Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET

Company Participants

Paul Goodson - Investor Relations
Wenbin Jiang - Chief Executive Officer
William McCombe - Chief Financial Officer

Conference Call Participants

Tejas Savant - Morgan Stanley
Jake Siewert - Goldman Sachs
David Westenberg - Piper Sandler
Noah Krozel - Raymond James
Mason Carrico - Stephens
Jacqueline Kisa - TD Cowen

Operator

Thank you for standing by. My name is Liz, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Cytek Biosciences First Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. [Operator Instructions]

I would now like to turn the call over to Paul Goodson, Investor Relations. Please go ahead.

Paul Goodson

Thank you, operator. Earlier today, Cytek Biosciences released financial results for the quarter ended March 31, 2024. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an email to investors@cytekbio.com. Joining me today from Cytek are Wenbin Jiang, CEO; and newly appointed CFO, Bill McCombe.

Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of the federal securities laws, including statements regarding Cytek's business plans, strategies, opportunities and financial projections. These statements are based on the company's current expectations and inherently involve significant risks and uncertainties that could cause actual results or events to materially differ from those anticipated.

Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release Cytek issued today and in Cytek's filings with the SEC. This call will also include a discussion of certain financial measures that are not calculated in accordance with generally accepted accounting principles. Reconciliation to the most directly comparable GAAP financial measure may be found in today's earnings release submitted to the SEC. Except as required by law, Cytek disclaims any duty to update any forward-looking statements whether because of new information, future events or changes in its expectations. This conference call contains time sensitive information and is accurate only as of the live broadcast, May 8, 2024.

Before Wenbin speaks, I would like to mention that Cytek will be participating in a variety of industry and academic conferences, meetings and seminars throughout 2024. While these are primarily geared to the scientific community, they may offer an opportunity to interact with uses of our technologies to learn by Cytek instruments are so highly valued by our customers. There is a cost to attend most events, and we have a limited number of spaces to accommodate members of the financial community. So if you are interested in attending, please contact me.